Lite Strategy Inc. Faces Turbulent Times: Insider Buy Sparks Investor Speculation Amid Biotech Challenges
Lite Strategy Inc. (LITS) faces a tough biotech journey with steep stock declines, negative earnings, and insider moves—yet its cancer‑metabolism therapy research could spark a turnaround for investors looking for breakthrough opportunities.
3 minutes to read